Keytruda

pembrolizumab
PD-1 Inhibitor Merck FDA Monitored

Safety Profile Overview

Anti-PD-1 checkpoint inhibitor approved for multiple cancer types. The world's top-selling drug by revenue. FDA monitors for immune-mediated adverse reactions across all organ systems.

Generic Name
pembrolizumab
Brand Names
Keytruda
Therapeutic Class
PD-1 Inhibitor
Manufacturer
Merck

What Pharma Signal Tracks for Keytruda

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Keytruda Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Keytruda.

curl "https://api.pharma-signal.com/drug/safety/keytruda" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Keytruda against other PD-1 Inhibitor drugs, or explore the full manufacturer portfolio for Merck.